Pricing Availability   Qty
Cat.No. 0341 - L-AP6 | C6H14NO5P | CAS No. 78944-89-5
Description: Selective agonist of the 'quis' effect
Chemical Name: L-(+)-2-Amino-6-phosphonohexanoic acid

Biological Activity

Selective agonist for 'quis'-sensitized site.

Technical Data

M. Wt 211.15
Formula C6H14NO5P
Storage Store at RT
CAS Number 78944-89-5
PubChem ID 3062646
Smiles [H][C@@](CCCCP(O)(O)=O)(N)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solubility Soluble to 100 mM in 1eq. NaOH


References are publications that support the biological activity of the product.

Johansen et al (1995) Type 4a metabotropic glutamate receptor: identification of new potent agonists and differentiation from the L-(+)-2-amino-4-phosphonobutanoic acid-sensitive receptor in the lateral perforant pathway in rats. Mol.Pharmacol. 48 140 PMID: 7623768

Schulte et al (1994) Utilization of the resolved L-isomer of 2-amino-6-phosphonohexanoic acid (L-AP6) as a selective agonist for a quisqualate-sensitized site in hippocampal CA1 pyramidal neurons. Brain Res. 649 203 PMID: 7953634

Venkatraman et al (1994) Synthesis of oxadiazolidinedione derivatives as quisqualic acid analogues and their evaluation at a quisqualate-sensitized site in the rat hippocampus. J.Med.Chem. 37 3939 PMID: 7966155

If you know of a relevant reference for L-AP6, please let us know.

Keywords: L-AP6, L-AP6 supplier, Selective, agonists, quis, effect, Glutamate, mGlur, Receptors, Metabotropic, iGluR, Ionotropic, Miscellaneous, 0341, Tocris Bioscience

Citations for L-AP6

Citations are publications that use Tocris products.

Currently there are no citations for L-AP6. Do you know of a great paper that uses L-AP6 from Tocris? Please let us know.

Reviews for L-AP6

There are currently no reviews for this product. Be the first to review L-AP6 and earn rewards!

Have you used L-AP6?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Metabotropic Glutamate Receptors

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.


Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Learning & Memory

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.


Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.